Recent Finacing
Recent Raise
GPN Vaccines develops Gamma-PN, a broad-spectrum pneumococcal vaccine candidate, currently in first-in-human trials in Australia evaluating serotype-independent opsonophagocytic antibody responses.
Focus Areas
Recent Investors
Valuation as of 06/05/2024
Total Raised
Funding rounds
Investors
